TR201808169T3 - Rekombinant probiyotik bakteriler . - Google Patents
Rekombinant probiyotik bakteriler . Download PDFInfo
- Publication number
- TR201808169T3 TR201808169T3 TR2018/08169T TR201808169T TR201808169T3 TR 201808169 T3 TR201808169 T3 TR 201808169T3 TR 2018/08169 T TR2018/08169 T TR 2018/08169T TR 201808169 T TR201808169 T TR 201808169T TR 201808169 T3 TR201808169 T3 TR 201808169T3
- Authority
- TR
- Turkey
- Prior art keywords
- probiotic bacteria
- recombinant probiotic
- factor
- recombinant
- gene
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims abstract 36
- 239000006041 probiotic Substances 0.000 title claims abstract 35
- 230000000529 probiotic effect Effects 0.000 title claims abstract 35
- 235000018291 probiotics Nutrition 0.000 title claims abstract 35
- 230000005995 skin dysfunction Effects 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 206010052428 Wound Diseases 0.000 claims 7
- 208000027418 Wounds and injury Diseases 0.000 claims 7
- 230000001939 inductive effect Effects 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 208000025865 Ulcer Diseases 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 231100000397 ulcer Toxicity 0.000 claims 4
- 241000194035 Lactococcus lactis Species 0.000 claims 3
- 108010053775 Nisin Proteins 0.000 claims 3
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims 3
- 235000014897 Streptococcus lactis Nutrition 0.000 claims 3
- 239000004309 nisin Substances 0.000 claims 3
- 235000010297 nisin Nutrition 0.000 claims 3
- 108010062877 Bacteriocins Proteins 0.000 claims 2
- 108010066486 EGF Family of Proteins Proteins 0.000 claims 2
- 102000018386 EGF Family of Proteins Human genes 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 241000194036 Lactococcus Species 0.000 claims 2
- 102000013275 Somatomedins Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 229940028885 interleukin-4 Drugs 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 230000010287 polarization Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 108010041525 Alanine racemase Proteins 0.000 claims 1
- 108010070255 Aspartate-ammonia ligase Proteins 0.000 claims 1
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 claims 1
- 101100492477 Bacillus subtilis (strain 168) asnH gene Proteins 0.000 claims 1
- 102100039866 CTP synthase 1 Human genes 0.000 claims 1
- 108010018956 CTP synthetase Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 208000004898 Herpes Labialis Diseases 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 108700005443 Microbial Genes Proteins 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 206010067152 Oral herpes Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 claims 1
- 102000005497 Thymidylate Synthase Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 108010075344 Tryptophan synthase Proteins 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000004049 epigenetic modification Effects 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108010074461 nisin A Proteins 0.000 claims 1
- 108700042622 nisin Z Proteins 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 101150054232 pyrG gene Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 101150072314 thyA gene Proteins 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 230000009752 translational inhibition Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Buluş, bir deri disfonksiyonunun tedavisinde kullanım için rekombinant probiyotik bakterilere ve ayrıca bir deri disfonksiyonunun tedavisi için bir yönteme yöneliktir.
Claims (23)
- l . Bir ilk heterolog faktörün kodlanmasi için (a) nükleik asit dizisi/dizileri, bir ikinci heterolog faktörün kodlanmasi için (a) nükleik asit dizisi/dizileri ve tercihen söz konusu ilk faktör, söz konusu ikinci faktör ve söz konusu üçüncü faktörün fonksiyonel olarak birbirinden farkli olmasi kosuluyla bir üçüncü heterolog faktörün kodlanmasi için (a) nükleik asit dizisi/dizilerini içeren, söz konusu ilk faktörün bir büyüme faktörü oldugu, söz konusu ikinci faktörün M2 polarlasma faktörlerini içeren gruptan seçildigi ve tercihen söz konusu üçüncü faktörün ise M2 polarlasma faktörleri ve büyüme faktörlerini içeren gruptan seçildigi rekombinant probiyotik bakteriler.
- 2. Söz konusu nükleik asit dizisinin/dizilerinin söz konusu rekombinant probiyotik bakterilerinin bir kromozom ve bir plazmidinin en az biri üzerinde yer aldigi, Istem 1,deki gibi rekombinant probiyotik bakteriler.
- 3. Söz konusu nükleik asit dizisinin/dizilerinin bir ifadesinin bir konstitutif kolaylastirici veya bir uyarilabilir kolaylastirici tarafindan kontrol edildigi, Istem 1 veya 2,den herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 4. Söz konusu nükleik asit dizisinin/dizilerinin bir ifadesinin bir uyarilabilir kolaylastirici tarafindan kontrol edildigi, siz konusu nükleik asit dizilerinin/dizisinin en az bir uyarici varliginda ifade edilebilir oldugu, Istem 39teki gibi rekombinant probiyotik bakteriler.
- 5. Bir uyarici tarafindan indüklenebilen söz konusu uyarilabilir kolaylastiricinin, bir lantibiyotik peptit için bir fonksiyonel analogunu kodlayan bir mikrobiyal gen için bir kolaylastirici oldugu, burada sözü edilen uyarilabilir kolaylastiricinin tercihen PnisA, PnisZ, PnisQ, PnisF, PnisU veya Lactococcus lactis kombinasyonlari oldugu, Istem 3 veya 4”ten herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 6. Uyaricinin tercihen nisin A, nisin Z, nisin Q, nisin F, nisin U, bunlarin fonksiyonel analoglari ve karisimlarini içeren gruptan seçilen en az bir lantibiyotik peptit veya bunun bir fonksiyonel analogu oldugu, Istem 4 veya 59ten herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 7. Söz konusu probiyotik bakterilerin ayrica söz konusu probiyotik bakterilerin canliligi için gerekli olan bir temel proteini kodlayan en az bir aktive edilmemis geni içerdigi, Istem 1 ila 63dan herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 8. Söz konusu probiyotik bakterinin canliligi için gerekli en az bir aktive edilmemis genin alanin rasemaz (alaR), timidilat sentaz (thyA), asparagin sintaz (asnH), CTP sentaz (pyrG), triptofan sintaz (trpBA) ve bunlarin kombinasyonlarini içeren gruptan seçildigi, Istem 7°deki gibi rekombinant probiyotik bakteriler.
- 9. Söz konusu genin, söz konusu genin silinmesi, söz konusu genin mutasyonu, söz konusu genin epigenetik modifikasyonu, söz konusu genin RNA interferansi aracili gen baskilamasi, söz konusu genin translasyonal inhibisyonu veya bunlarin kombinasyonlari ile inaktive edildigi, Istem 7 veya 8,den herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 10. Söz konusu ilk faktör, söz konusu ikinci faktör veya söz konusu üçüncü faktörün en az birinin söz konusu rekombinant probiyotik bakterilerden serbest birakilabilir oldugu, Istemler 1 ila 9,dan herhangi birindeki gibi rekombinant probiyotik bakteriler.
- ll . Söz konusu M2-polarlastirici faktörün sitokinler, kemokinler ve bunlarin karisimlarini içeren gruptan seçildigi, Istemler 1 ila 105dan herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 12. Söz konusu M2-polarize edici faktörün, interlökin 4 (IL-4), interlökin 10 (IL- bunlarin karisimlarini içeren gruptan seçildigi, Istemler 1 ila 1 liden herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 13. Söz konusu büyüme faktörünün, fibroblast büyüme faktörleri (FGF), vasküler endotelyal büyüme faktörleri (VEGF), epidermal büyüme faktörleri (EGF), heparin baglayici EGP-benzeri büyüme faktörü (HB-EGF), transforme edici büyüme faktörü- a (TGF-a), insülin benzeri büyüme faktörleri (IGF), trombosit kaynakli büyüme faktörleri (PDGF), transforme edici büyüme faktörü beta (TGF- B) ve bunlarin karisimlari, tercihen fibroblast büyüme faktörü 2 (FGF-2) içeren gruptan seçildigi, Istemler 1 ila 11°den herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 14. Söz konusu rekombinant probiyotik bakterilerin laktik asit bakterileri, tercihen bir Lactobacillus veya bir Lactococcus türü oldugu, Istemler 1 ila 13,ten herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 15. Söz konusu Lactococcus türünün Lactococcus lactis, tercihen Lactococcus lactis alt türü cremoris oldugu, Istem 14,teki gibi rekombinant probiyotik bakteriler.
- 16. Söz konusu rekombinant probiyotik bakterilerin bir çözelti, dondurulmus veya kurutulmus, tercihen havasiz kurutulmus veya spreyle kurutulmus oldugu, Istemler 1 ila 15,ten herhangi birindeki gibi rekombinant probiyotik bakteriler.
- 17. Söz konusu rekombinant probiyotik bakterilerin topikal olarak ve/veya deri alti enjeksiyonu yoluyla uygulandigi, Istemler 1 ila 16,dan herhangi birindeki gibi rekombinant probiyotik bakteriler
- 18. Söz konusu probiyotik bakterilerin Istemler 1 ila 17,den herhangi birindeki gibi rekombinant probiyotik bakteriler oldugu, enflamatuar deri disfonksiyonunun tedavisindeki kullanim için rekombinant probiyotik bakteriler.
- 19. Söz konusu enflamatuar deri disfonksiyonunun bir enflamatuar deri hastaligi veya bir enflamatuar bag dokusu hastaligi oldugu, Istem 18ideki gibi rekombinant probiyotik bakteriler.
- 20. Söz konusu enflamatuar deri hastaliginin, soguk yakmasi, egzama, sedef hastaligi, dermatit, ülser, yara, lupus eritematozus, nörodermit veya bunlarin kombinasyonlari oldugu, Istem 19Sdaki gibi rekombinant probiyotik bakteriler.
- 21 . Söz konusu yaranin bir yanik yarasi, bir kimyasal yara, bir radyasyon kaynakli yara, bir iskemik yara veya bir mekanik yara oldugu, Istem 20,deki gibi rekombinant probiyotik bakteriler.
- 22. Söz konusu ülserin bir dekübitus ülseri veya bir ulkus ülseri oldugu, Istem 20,deki gibi rekombinant probiyotik bakteriler.
- 23. Söz konusu yöntemin Istemler 1 ila 223den herhangi birindeki gibi rekombinant probiyotik bakterilerin söz konusu enflamatuar deri disfonksiyonundan muzdarip bir kisiye uygulanmasi adimini içeren, bir enflamatuar deri disfonksiyonunun tedavisi için yöntem.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/052345 WO2016124239A1 (en) | 2015-02-04 | 2015-02-04 | Recombinant probiotic bacteria for use in the treatment of a skin dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201808169T3 true TR201808169T3 (tr) | 2018-07-23 |
Family
ID=53039847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/08169T TR201808169T3 (tr) | 2015-02-04 | 2015-11-02 | Rekombinant probiyotik bakteriler . |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10738315B2 (tr) |
| EP (1) | EP3253402B1 (tr) |
| JP (1) | JP6726419B2 (tr) |
| KR (1) | KR102172228B1 (tr) |
| CN (1) | CN107438666B (tr) |
| AU (1) | AU2015381262B2 (tr) |
| BR (1) | BR112017016772A2 (tr) |
| CA (1) | CA2975636C (tr) |
| CY (2) | CY20182200002T2 (tr) |
| DE (1) | DE15821025T8 (tr) |
| DK (1) | DK3253402T3 (tr) |
| ES (1) | ES2673007T3 (tr) |
| HR (1) | HRP20200973T1 (tr) |
| HU (1) | HUE050790T2 (tr) |
| IL (1) | IL253782B (tr) |
| LT (1) | LT3253402T (tr) |
| MX (1) | MX2017010150A (tr) |
| NZ (1) | NZ734579A (tr) |
| PL (1) | PL3253402T3 (tr) |
| PT (1) | PT3253402T (tr) |
| RS (1) | RS60437B1 (tr) |
| RU (1) | RU2723324C2 (tr) |
| SG (1) | SG11201706398VA (tr) |
| SI (1) | SI3253402T1 (tr) |
| TR (1) | TR201808169T3 (tr) |
| WO (2) | WO2016124239A1 (tr) |
| ZA (1) | ZA201705812B (tr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015370982B2 (en) | 2014-12-23 | 2019-03-21 | Ilya Pharma Ab | Methods for wound healing |
| RU2021135949A (ru) * | 2016-09-13 | 2022-04-14 | Интрексон Актобиотикс Н.В. | Мукоадгезивный микроорганизм |
| US11850270B2 (en) | 2017-12-04 | 2023-12-26 | The BioCollective, LLC | Probiotics and methods of use |
| WO2019162935A1 (en) * | 2018-02-24 | 2019-08-29 | Clearskin Ltd | Compositions, devices, systems, kits and methods for the treatment of a skin condition |
| EP3837993A4 (en) * | 2018-06-19 | 2022-04-20 | Coenbio Co., Ltd. | COMPOSITION FOR IMPROVING INTESTINAL FUNCTION WITH LEUCONOSTOC SP. STRAIN |
| WO2019245223A1 (ko) * | 2018-06-19 | 2019-12-26 | (주)코엔바이오 | 류코노스톡속 균주를 포함하는 간 기능 개선용 조성물 |
| KR102173168B1 (ko) * | 2018-06-19 | 2020-11-03 | 주식회사 엠디헬스케어 | 류코노스톡속 균주를 포함하는 장 기능 개선용 조성물 |
| KR102283127B1 (ko) * | 2018-06-19 | 2021-07-29 | 주식회사 엠디헬스케어 | 류코노스톡속 균주를 포함하는 간 기능 개선용 조성물 |
| US20220177533A1 (en) * | 2018-08-08 | 2022-06-09 | Sree Chitra Tirunal Institute For Medical Sciences And Technology | Recombinant TGF a for wound healing purposes, and the process thereof |
| CN109078171A (zh) * | 2018-09-10 | 2018-12-25 | 因之彩生物科技（武汉）有限公司 | 一种外用组合物及其应用以及外用治疗剂 |
| PL3921422T3 (pl) * | 2019-03-04 | 2024-04-02 | Aurealis Therapeutics AG | Indukowalny chlorkiem prokariotyczny układ ekspresji |
| IT201900003115A1 (it) * | 2019-03-04 | 2020-09-04 | Univ Degli Studi Roma La Sapienza | Lattococco ingegnerizzato |
| CN112175890A (zh) * | 2019-07-02 | 2021-01-05 | 深伦生物科技（深圳）有限公司 | 一种以食用菌分泌乙醇脱氢酶的基因工程菌 |
| KR102343938B1 (ko) * | 2020-09-02 | 2021-12-28 | 주식회사 비피도 | 재조합 비피도박테리움 비피덤 bgn4를 포함하는 염증 개선용 조성물 |
| CN112359049B (zh) * | 2020-12-10 | 2022-01-28 | 昆明理工大学 | 一种岷江百合几丁质酶基因LrCHI2及其应用 |
| KR102253283B1 (ko) * | 2020-12-21 | 2021-05-18 | 주식회사 비피도 | 비피도박테리움 비피덤을 이용한 인간 egf 단백질의 생산방법 및 이를 함유하는 조성물 |
| JP2024508541A (ja) * | 2021-03-05 | 2024-02-27 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | 皮膚プロバイオティクス |
| CN114395514B (zh) * | 2022-02-28 | 2023-09-01 | 鲁东大学 | 一株嗜酸乳杆菌、菌剂及其应用 |
| CN114957437B (zh) * | 2022-06-06 | 2023-03-21 | 陕西理工大学 | 一种leap-2重组蛋白和一种重组乳酸乳球菌及其应用 |
| CN115181710B (zh) * | 2022-09-13 | 2022-11-25 | 北京量化健康科技有限公司 | 一株唾液乳杆菌b12wu及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005111194A1 (en) | 2004-05-18 | 2005-11-24 | Vib Vzw | Self-containing lactobacillus strain |
| US8682619B2 (en) * | 2005-12-14 | 2014-03-25 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| JP5584470B2 (ja) | 2007-01-12 | 2014-09-03 | アクトジェニックス・エヌブイ | ラクトコッカスプロモーター及びその使用 |
| US20100178273A1 (en) * | 2007-06-20 | 2010-07-15 | Actogenix Nv Corporation | Methods and compositions for treating mucositis |
| CN102027123B (zh) * | 2008-03-14 | 2016-03-16 | 人体酶有限公司 | 使用人细胞表达系统重组产生可靠的人蛋白质 |
| CN102224245B (zh) * | 2008-09-30 | 2016-01-13 | 诺维信股份有限公司 | 在丝状真菌细胞中使用阳性和阴性选择性基因的方法 |
| ES2549158T3 (es) | 2008-11-11 | 2015-10-23 | Signum Biosciences, Inc. | Compuestos de isoprenilo y métodos de los mismos |
| WO2010090845A1 (en) * | 2009-01-20 | 2010-08-12 | Signum Biosciences, Inc. | Anti-inflammatory complexes |
| FR2948868B1 (fr) * | 2009-08-07 | 2011-10-07 | Anthogyr Sa | Piece a main a moyens de connexion electrique |
| BR112012016982B8 (pt) * | 2010-01-14 | 2022-12-20 | Institut National De Rech Pour Lagriculture Lalimentation Et Lenvironnement | bactéria de ácido lático recombinante de grau alimentício e composição terapêutica |
| US20130078275A1 (en) * | 2010-05-25 | 2013-03-28 | The Board Of Trustees Of The University Of Illinois | Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells |
| CN103189504B (zh) * | 2010-06-18 | 2017-05-24 | 北卡罗莱纳州立大学 | 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌 |
| CN101892189B (zh) | 2010-07-05 | 2012-07-04 | 浙江大学 | 一种口服免疫阻断猪生长抑素作用的转化子及其应用 |
| JP2012019768A (ja) * | 2010-07-16 | 2012-02-02 | Osaka Univ | Ｊｍｊｄ３遺伝子改変非ヒト哺乳動物、Ｊｍｊｄ３遺伝子改変骨髄キメラ非ヒト哺乳動物、及びその利用 |
| TWI566701B (zh) | 2012-02-01 | 2017-01-21 | 日本農藥股份有限公司 | 芳烷氧基嘧啶衍生物及包含該衍生物作為有效成分的農園藝用殺蟲劑及其使用方法 |
| GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
| TWI613833B (zh) | 2012-11-09 | 2018-02-01 | Sony Corp | 光電變換元件、固體攝像裝置及電子機器 |
| AU2013344878A1 (en) * | 2012-11-16 | 2015-05-21 | Allergan, Inc. | Skin wound healing and scar reduction with prostaglandin EP4 agonist combinations |
| WO2015195845A1 (en) | 2014-06-17 | 2015-12-23 | Xycrobe Therapeutics, Inc. | Genetically modified bacteria and methods for genetic modification of bacteria |
-
2015
- 2015-02-04 WO PCT/EP2015/052345 patent/WO2016124239A1/en active Application Filing
- 2015-11-02 PL PL15821025T patent/PL3253402T3/pl unknown
- 2015-11-02 AU AU2015381262A patent/AU2015381262B2/en active Active
- 2015-11-02 DK DK15821025.2T patent/DK3253402T3/da active
- 2015-11-02 KR KR1020177024852A patent/KR102172228B1/ko active IP Right Grant
- 2015-11-02 HU HUE15821025A patent/HUE050790T2/hu unknown
- 2015-11-02 EP EP15821025.2A patent/EP3253402B1/en active Active
- 2015-11-02 RS RS20200690A patent/RS60437B1/sr unknown
- 2015-11-02 US US15/548,558 patent/US10738315B2/en active Active
- 2015-11-02 RU RU2017127991A patent/RU2723324C2/ru active
- 2015-11-02 DE DE15821025.2T patent/DE15821025T8/de active Active
- 2015-11-02 JP JP2017559760A patent/JP6726419B2/ja active Active
- 2015-11-02 SG SG11201706398VA patent/SG11201706398VA/en unknown
- 2015-11-02 CA CA2975636A patent/CA2975636C/en active Active
- 2015-11-02 NZ NZ73457915A patent/NZ734579A/en unknown
- 2015-11-02 LT LTEP15821025.2T patent/LT3253402T/lt unknown
- 2015-11-02 WO PCT/EP2015/075484 patent/WO2016124266A1/en active Application Filing
- 2015-11-02 CN CN201580078514.1A patent/CN107438666B/zh active Active
- 2015-11-02 MX MX2017010150A patent/MX2017010150A/es unknown
- 2015-11-02 BR BR112017016772-7A patent/BR112017016772A2/pt active Search and Examination
- 2015-11-02 SI SI201531265T patent/SI3253402T1/sl unknown
- 2015-11-02 PT PT158210252T patent/PT3253402T/pt unknown
- 2015-11-02 ES ES15821025T patent/ES2673007T3/es active Active
- 2015-11-02 TR TR2018/08169T patent/TR201808169T3/tr unknown
-
2017
- 2017-08-01 IL IL253782A patent/IL253782B/en unknown
- 2017-08-25 ZA ZA2017/05812A patent/ZA201705812B/en unknown
-
2018
- 2018-06-07 CY CY20182200002T patent/CY20182200002T2/el unknown
-
2020
- 2020-06-18 CY CY20201100564T patent/CY1123065T1/el unknown
- 2020-06-19 HR HRP20200973TT patent/HRP20200973T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201808169T3 (tr) | Rekombinant probiyotik bakteriler . | |
| Ong et al. | Novel non-angiogenic role for mesenchymal stem cell-derived vascular endothelial growth factor on keratinocytes during wound healing | |
| JP2017521059A5 (tr) | ||
| CN113403244B (zh) | 伤口愈合的方法 | |
| Alber et al. | The role of macrophages in healing the wounded lung | |
| US8409625B2 (en) | Conditioned decellularized native tissues for tissue restoration | |
| Kiwanuka et al. | Harnessing growth factors to influence wound healing | |
| Liu et al. | The essentiality and involvement of Streptococcus intermedius histone‐like DNA‐binding protein in bacterial viability and normal growth | |
| MX2021011039A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. | |
| Sabin et al. | The role of the immune system during regeneration of the central nervous system | |
| Yang et al. | The Angiogenic Peptide Vascular Endothelial Growth Factor–Basic Fibroblast Growth Factor Signaling is Up‐Regulated in a Rat Pressure Ulcer Model | |
| HRP20240085T1 (hr) | Prokariotski ekspresijski sustav indukciran kloridom | |
| Su et al. | Down-regulation of hepatocyte growth factor mRNA in rat cardiac myocytes under hypoxia mimicked by cobalt chloride | |
| RU2021126069A (ru) | Хлорид-индуцируемая прокариотическая система экспрессии | |
| Chen et al. | Fibroblast: A Novel Target for Autoimmune and Inflammatory Skin Diseases Therapeutics | |
| Maleszewska et al. | IL-1b and TGFb2 synergistically induce endothelial to mesenchymal transition in an NFjB-dependent manner | |
| TWI472615B (zh) | 生產可溶性重組三葉因子胜肽之轉形株及可溶性重組三葉因子胜肽之製造方法 | |
| Tarakanov et al. | Expression vector pLF22 for lactic acid bacteria | |
| Plyasunova | MAKING TRANSGENIC AXOLOTL FOR LINEAGE TRACING CONNECTIVE TISSUES DURING LIMB REGENERATION | |
| Patodia | Transcriptional regulation and downstream effectors of peripheral nerve regeneration |